Bio-Techne (Exosome Diagnostics) Presents Initial Data on Sjogren’s Syndrome; Novel Diagnostic & Monitoring Tool Leverages Extracellular Vesicles (EVs) to Monitor RNA Transcriptome from Small Saliva Sample

On September 8, 2022, Bio-Techne Corporation (NASDAQ:TECH) announced that Exosome Diagnostics, a Bio-Techne brand, would present initial data on its novel non-invasive saliva profiling assay for Sjögren's syndrome diagnosis and monitoring at the 15th International Symposium on Sjögren's Syndrome in Rome, Italy on Friday, September 9. Exosome Diagnostics' novel Sjögren's syndrome diagnostic and monitoring tool leverages extracellular vesicles (EVs) to monitor the RNA transcriptome from a small saliva sample. The data presented highlights a ground-breaking non-invasive monitoring tool to diagnose and understand the pathogenesis of Sjögren's syndrome from a small saliva sample, with potential applications for other autoimmune diseases. The presentation was given by Exosome Diagnostics study collaborator, Athena Papas, DMD, PhD, Professor of Diagnostic Sciences at Tufts School of Dental Medicine (Boston, Massachusetts) and carries the title "Identification of a Saliva Exosomal-RNA Signature for Sjögren's Syndrome.” The study included saliva from Sjögren's Syndrome patients, as well as from other autoimmune disease patients, including ones with systemic lupus erythematosus and rheumatoid arthritis, as well as necessary controls.

Login Or Register To Read Full Story